176 related articles for article (PubMed ID: 25488170)
21. An assessment of the likely acceptability of vaginal microbicides for HIV prevention among women in rural Ghana.
Abdulai MA; Baiden F; Adjei G; Afari-Asiedu S; Adjei K; Tawiah C; Newton S
BMC Womens Health; 2012 Nov; 12():40. PubMed ID: 23114222
[TBL] [Abstract][Full Text] [Related]
22. Communicating about microbicides with women in mind: tailoring messages for specific audiences.
Sidibe S; Pack AP; Tolley EE; Ryan E; Mackenzie C; Bockh E; Githuka G
J Int AIDS Soc; 2014; 17(3 Suppl 2):19151. PubMed ID: 25224612
[TBL] [Abstract][Full Text] [Related]
23. Acceptability of a microbicide among women and their partners in a 4-country phase I trial.
Bentley ME; Fullem AM; Tolley EE; Kelly CW; Jogelkar N; Srirak N; Mwafulirwa L; Khumalo-Sakutukwa G; Celentano DD
Am J Public Health; 2004 Jul; 94(7):1159-64. PubMed ID: 15226137
[TBL] [Abstract][Full Text] [Related]
24. Sexuality, HIV risk and potential acceptability of involving adolescent girls in microbicide research in Kisumu, Kenya.
Montandon M; Sahin-Hodoglugil NN; Bukusi E; Agot K; Boland B; Cohen CR
Sex Health; 2008 Dec; 5(4):339-46. PubMed ID: 19061553
[TBL] [Abstract][Full Text] [Related]
25. Challenges to microbicide introduction in South Africa.
Orner P; Harries J; Cooper D; Moodley J; Hoffman M; Becker J; McGrory E; Dabash R; Bracken H
Soc Sci Med; 2006 Aug; 63(4):968-78. PubMed ID: 16600447
[TBL] [Abstract][Full Text] [Related]
26. Acceptability and performance of a nonwoven device for vaginal drug delivery among women and their male partners in KwaZulu-Natal, South Africa.
Hart CW; Joanis C; Hartmann M; Milford C; Smit J; Beksinska M; Rambally-Greener L; Pienaar J; Mabude Z; Butterworth GAM; Sokal D; Jenkins D
Eur J Contracept Reprod Health Care; 2019 Oct; 24(5):390-398. PubMed ID: 31517545
[No Abstract] [Full Text] [Related]
27. High acceptability of a vaginal ring intended as a microbicide delivery method for HIV prevention in African women.
van der Straten A; Montgomery ET; Cheng H; Wegner L; Masenga G; von Mollendorf C; Bekker L; Ganesh S; Young K; Romano J; Nel A; Woodsong C
AIDS Behav; 2012 Oct; 16(7):1775-86. PubMed ID: 22644068
[TBL] [Abstract][Full Text] [Related]
28. The relationship between vaginal ring use and intimate partner violence and social harms: formative research outcomes from the CHARISMA study in Johannesburg, South Africa.
Hartmann M; Palanee-Phillips T; O'Rourke S; Adewumi K; Tenza S; Mathebula F; Wagner D; Ayub A; Montgomery ET
AIDS Care; 2019 Jun; 31(6):660-666. PubMed ID: 30309246
[TBL] [Abstract][Full Text] [Related]
29. Muslim women's reflections on the acceptability of vaginal microbicidal products to prevent HIV infection.
Hoel N; Shaikh S; Kagee A
Ethn Health; 2011 Apr; 16(2):89-106. PubMed ID: 21328113
[TBL] [Abstract][Full Text] [Related]
30. Intravaginal practices and microbicide acceptability in Papua New Guinea: implications for HIV prevention in a moderate-prevalence setting.
Vallely A; Fitzgerald L; Fiya V; Aeno H; Kelly A; Sauk J; Kupul M; Neo J; Millan J; Siba P; Kaldor JM
BMC Res Notes; 2012 Nov; 5():613. PubMed ID: 23116431
[TBL] [Abstract][Full Text] [Related]
31. Women's interest in vaginal microbicides.
Darroch JE; Frost JJ
Fam Plann Perspect; 1999; 31(1):16-23. PubMed ID: 10029928
[TBL] [Abstract][Full Text] [Related]
32. Trial participation disclosure and gel use behavior in the CAPRISA 004 tenofovir gel trial.
Succop SM; MacQueen KM; van Loggerenberg F; Majola N; Karim QA; Karim SS
AIDS Care; 2014; 26(12):1521-5. PubMed ID: 25285564
[TBL] [Abstract][Full Text] [Related]
33. Gender relations in the context of HIV/AIDS in rural South Africa.
Ndinda C; Uzodike UO; Chimbwete C; Pool R;
AIDS Care; 2007 Aug; 19(7):844-9. PubMed ID: 17712686
[TBL] [Abstract][Full Text] [Related]
34. Hidden heterogeneity: Uncovering patterns of adherence in microbicide trials for HIV prevention.
Miller L; Prieto Merino D; Baisley K; Hayes R
PLoS One; 2022; 17(5):e0267011. PubMed ID: 35551324
[TBL] [Abstract][Full Text] [Related]
35. Sexual pleasure, gender power and microbicide acceptability in Zimbabwe and Malawi.
Woodsong C; Alleman P
AIDS Educ Prev; 2008 Apr; 20(2):171-87. PubMed ID: 18433322
[TBL] [Abstract][Full Text] [Related]
36. Disclosure of microbicide gel use to sexual partners: influence on adherence in the CAPRISA 004 trial.
Mngadi KT; Maarschalk S; Grobler AC; Mansoor LE; Frohlich JA; Madlala B; Ngcobo N; Abdool Karim SS; Abdool Karim Q
AIDS Behav; 2014 May; 18(5):849-54. PubMed ID: 24633715
[TBL] [Abstract][Full Text] [Related]
37. Re-framing microbicide acceptability: findings from the MDP301 trial.
Montgomery CM; Gafos M; Lees S; Morar NS; Mweemba O; Ssali A; Stadler J; Pool R;
Cult Health Sex; 2010 Aug; 12(6):649-62. PubMed ID: 20397079
[TBL] [Abstract][Full Text] [Related]
38. Willingness of clinicians to integrate microbicides into HIV prevention practices in southern Africa.
Harper CC; Holt K; Nhemachena T; Chipato T; Ramjee G; Stratton L; Blum M; McCulloch CE; Mgweba S; Blanchard K
AIDS Behav; 2012 Oct; 16(7):1821-9. PubMed ID: 22210482
[TBL] [Abstract][Full Text] [Related]
39. Topical microbicides for prevention of sexually transmitted infections.
Obiero J; Mwethera PG; Wiysonge CS
Cochrane Database Syst Rev; 2012 Jun; (6):CD007961. PubMed ID: 22696373
[TBL] [Abstract][Full Text] [Related]
40. Health practices and vaginal microbicide acceptability among urban black women.
Reiff M; Wade C; Chao MT; Kronenberg F; Cushman LF
J Womens Health (Larchmt); 2008 Oct; 17(8):1345-51. PubMed ID: 18788991
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
